A survey of Australian public attitudes towards funding of high cost cancer medicines

Narcyz Ghinea, Christine Critchley, Bronwen Morrell, Ian Kerridge, Terry Campbell, Richard Day, Madlen Gazarian, David Isaacs, Winston Liauw, Ian Olver, Jessica Pace, Sallie Pearson, Glenn Salkeld and Wendy Lipworth

Health Policy, 2021, vol. 125, issue 3, 327-334

Abstract: In the past decade many novel, and in some cases transformative, cancer medicines have entered the market. Their prices and the amount spent on them by governments have increased rapidly, bringing to the forefront trade-offs that must be made. In this paper we explore the Australian public’s attitude towards the funding of high cost cancer medicines (HCCM) to inform reimbursement and health technology assessment (HTA) policy.

Keywords: Health equity; Access to health care; Health insurance; Cancer; Health care technology; High-cost medicines (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851020303018
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:125:y:2021:i:3:p:327-334

DOI: 10.1016/j.healthpol.2020.12.002

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().